[go: up one dir, main page]

NO20021474D0 - Forbindelser for behandling av ischemi - Google Patents

Forbindelser for behandling av ischemi

Info

Publication number
NO20021474D0
NO20021474D0 NO20021474A NO20021474A NO20021474D0 NO 20021474 D0 NO20021474 D0 NO 20021474D0 NO 20021474 A NO20021474 A NO 20021474A NO 20021474 A NO20021474 A NO 20021474A NO 20021474 D0 NO20021474 D0 NO 20021474D0
Authority
NO
Norway
Prior art keywords
ischemia
compounds
treatment
Prior art date
Application number
NO20021474A
Other languages
English (en)
Other versions
NO20021474L (no
Inventor
Hiroko Masamune
Michael Paul Deninno
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20021474D0 publication Critical patent/NO20021474D0/no
Publication of NO20021474L publication Critical patent/NO20021474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
NO20021474A 1999-09-30 2002-03-25 Forbindelser for behandling av ischemi NO20021474L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (2)

Publication Number Publication Date
NO20021474D0 true NO20021474D0 (no) 2002-03-25
NO20021474L NO20021474L (no) 2002-05-22

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021474A NO20021474L (no) 1999-09-30 2002-03-25 Forbindelser for behandling av ischemi

Country Status (41)

Country Link
EP (1) EP1216257B1 (no)
JP (1) JP2003510331A (no)
KR (1) KR100481605B1 (no)
CN (1) CN1374967A (no)
AP (1) AP2002002458A0 (no)
AR (1) AR029887A1 (no)
AT (1) ATE312117T1 (no)
AU (1) AU778185B2 (no)
BG (1) BG106636A (no)
BR (1) BR0014384A (no)
CA (1) CA2386079A1 (no)
CO (1) CO5180581A1 (no)
CR (1) CR6592A (no)
CZ (1) CZ20021020A3 (no)
DE (1) DE60024649D1 (no)
EA (1) EA005422B1 (no)
EC (1) ECSP003682A (no)
EE (1) EE200200172A (no)
GE (1) GEP20043241B (no)
GT (1) GT200000161A (no)
HK (1) HK1049011A1 (no)
HR (1) HRP20020253A2 (no)
HU (1) HUP0202807A3 (no)
IL (1) IL148222A0 (no)
IS (1) IS6286A (no)
MA (1) MA26822A1 (no)
MX (1) MXPA02003308A (no)
MY (1) MY133996A (no)
NO (1) NO20021474L (no)
NZ (1) NZ517177A (no)
OA (1) OA12021A (no)
PA (1) PA8503301A1 (no)
PE (1) PE20010696A1 (no)
PL (1) PL357371A1 (no)
SK (1) SK4182002A3 (no)
TN (1) TNSN00191A1 (no)
TR (1) TR200200843T2 (no)
UA (1) UA73525C2 (no)
WO (1) WO2001023399A1 (no)
YU (1) YU23102A (no)
ZA (1) ZA200202461B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
BR0213820A (pt) * 2001-11-02 2004-08-31 Aventis Pharma Inc Composição farmacêutica que compreende um agonista de adenosina a1/a2 e um inibidor de trocador de sódio-hidrogênio
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AU2004289690A1 (en) * 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US8293791B2 (en) 2004-03-24 2012-10-23 Fasgen, Llc Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
ES2525319T3 (es) 2004-05-07 2014-12-22 Janssen Pharmaceutica Nv Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP4642847B2 (ja) * 2004-07-28 2011-03-02 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
EP1781331A1 (en) * 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
EP1786774B1 (en) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
UA87328C2 (en) * 2004-08-30 2009-07-10 Янссен Фармацевтика Н.В. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (no) 2009-08-17 2015-08-21 Intellikine Llc
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
ES2699646T3 (es) 2012-05-08 2019-02-12 Aeromics Inc Compuestos para uso en el tratamiento de enfermedades mediadas por acuaporina
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
HK1224228A1 (zh) * 2013-11-06 2017-08-18 Aeromics, Inc. 新型制剂
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX373272B (es) 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (no) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten

Also Published As

Publication number Publication date
DE60024649D1 (de) 2006-01-12
CN1374967A (zh) 2002-10-16
HK1049011A1 (zh) 2003-04-25
KR100481605B1 (ko) 2005-04-08
ZA200202461B (en) 2003-05-28
TNSN00191A1 (fr) 2005-11-10
GT200000161A (es) 2002-03-22
EA200200316A1 (ru) 2002-08-29
AU7035200A (en) 2001-04-30
CZ20021020A3 (cs) 2003-04-16
BR0014384A (pt) 2002-07-02
GEP20043241B (en) 2004-05-25
OA12021A (en) 2006-04-19
PE20010696A1 (es) 2001-07-05
PL357371A1 (en) 2004-07-26
KR20020034206A (ko) 2002-05-08
CA2386079A1 (en) 2001-04-05
IL148222A0 (en) 2002-09-12
MY133996A (en) 2007-11-30
AR029887A1 (es) 2003-07-23
BG106636A (bg) 2003-01-31
MA26822A1 (fr) 2004-12-20
WO2001023399A1 (en) 2001-04-05
CO5180581A1 (es) 2002-07-30
HUP0202807A2 (hu) 2002-12-28
EP1216257B1 (en) 2005-12-07
CR6592A (es) 2004-02-23
SK4182002A3 (en) 2003-04-01
JP2003510331A (ja) 2003-03-18
NO20021474L (no) 2002-05-22
ATE312117T1 (de) 2005-12-15
AP2002002458A0 (en) 2002-06-30
ECSP003682A (es) 2002-04-23
TR200200843T2 (tr) 2002-07-22
EP1216257A1 (en) 2002-06-26
PA8503301A1 (es) 2003-06-30
IS6286A (is) 2002-02-26
YU23102A (sh) 2006-01-16
EA005422B1 (ru) 2005-02-24
MXPA02003308A (es) 2002-10-04
NZ517177A (en) 2003-10-31
EE200200172A (et) 2003-06-16
HUP0202807A3 (en) 2005-02-28
HRP20020253A2 (en) 2004-04-30
AU778185B2 (en) 2004-11-18
UA73525C2 (en) 2005-08-15

Similar Documents

Publication Publication Date Title
NO20021474D0 (no) Forbindelser for behandling av ischemi
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20022979D0 (no) Anvendelse av organiske forbindelser
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
EE200100502A (et) Ühendid
ZA991578B (en) Compounds for the treatment of ischemia.
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20022087L (no) Fremgangsmåte for behandling av diabetes
NO20015288D0 (no) Anvendelse av makrolide forbindelser for behandling av tört öye
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20033804L (no) Karbamatforbindelser for behandling av smerte
NO20013769L (no) Kalsilytiske forbindelser
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20020466D0 (no) Kalsilytiske forbindelser
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20014262D0 (no) Tiazoloindolinon-forbindelser
NO20005479L (no) sPLA2-hemmende forbindelser til behandling av sykdom
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
PT1175417E (pt) Compostos substituidos de benzolactamas